Physician profile
Michael James Oconnell
NPI 1083691885
$13,942.38
in general payments reported to CMS, 2019-2025
28 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,993 · 2020: $1,888 · 2021: $2,676 · 2022: $2,493 · 2023: $1,870 · 2024: $1,561 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,892.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,031.57 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,441.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,341.54 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Esperion Therapeutics, INC. | $1,200.75 | 2020-2022 | |
| Pfizer INC. | $1,095.39 | 2019-2025 | |
| Abbvie INC. | $1,036.37 | 2019-2025 | |
| Amgen INC. | $979.26 | 2020-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $913.13 | 2019-2023 | Nucala, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $799.66 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.94 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $329.24 | 2019-2022 | |
| Allergan, INC. | $200.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $174.40 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.29 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.93 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $112.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.90 | 2020-2022 | |
| Exact Sciences Corporation | $90.34 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $80.39 | 2020-2021 | |
| Dexcom, INC. | $48.11 | 2021-2023 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $47.89 | 2021 | |
| Abbott Laboratories | $47.74 | 2022 | |
| Idorsia Pharmaceuticals US INC | $46.08 | 2022-2023 | Quviviq |
| Eisai INC. | $26.34 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.58 | 2024 | |
| Zyla Life Sciences, INC. | $15.70 | 2019 | |
| Shire North American Group INC | $14.43 | 2019 | |
| Adlon Therapeutics L.P. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Oconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.